Iright
BRAND / VENDOR: CST

CST, 3189S, Fatty Acid Synthase Antibody

CATALOG NUMBER: 3189S
Regular price$0.99
/
Shipping calculated at checkout.
  • ddddd

    99 xxxxxx

  • Backordered, shipping soon

This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.

Product Description
Polyclonal Antibody for studying FASN mouse. Validated for Western Blotting. Highly specific and rigorously validated in-house, Fatty Acid Synthase Antibody (CST #3189) is ready to ship. Product Usage Information Western Blotting: 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting Specificity / Sensitivity Fatty Acid Synthase Antibody detects endogenous levels of total fatty acid synthase protein. Species Reactivity: Human, Mouse Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide around Ala1160 corresponding to a sequence of mouse fatty acid synthase. Antibodies are purified by protein A and peptide affinity chromatography. Background Fatty acid synthase (FASN) catalyzes the synthesis of long-chain fatty acids from acetyl-CoA and malonyl-CoA. FASN is active as a homodimer with seven different catalytic activities and produces lipids in the liver for export to metabolically active tissues or storage in adipose tissue. In most other human tissues, FASN is minimally expressed since they rely on circulating fatty acids for new structural lipid synthesis (1). According to the research literature, increased expression of FASN has emerged as a phenotype common to most human carcinomas. For example, in breast cancer, immunohistochemical staining showed that the levels of FASN are directly related to the size of breast tumors (2). Research studies also showed that FASN is highly expressed in lung and prostate cancers and that FASN expression is an indicator of poor prognosis in breast and prostate cancer (3-5). Furthermore, inhibition of FASN is selectively cytotoxic to human cancer cells (5). Thus, increased interest has focused on FASN as a potential target for the diagnosis and treatment of cancer as well as metabolic syndrome (6,7). Alternate Names [Acyl-carrier-protein] S-acetyltransferase; [Acyl-carrier-protein] S-malonyltransferase; 3-hydroxyacyl-[acyl-carrier-protein] dehydratase; 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase; 3-oxoacyl-[acyl-carrier-protein] reductase; 3-oxoacyl-[acyl-carrier-protein] synthase; A630082H08Rik; Acyl-[acyl-carrier-protein] hydrolase; Enoyl-[acyl-carrier-protein] reductase; FAS; Fasn; Fatty acid synthase; Oleoyl-[acyl-carrier-protein] hydrolase; OTTMUSP00000004562; Type I Fatty Acid Synthase Specification REACTIVITY: H M SENSITIVITY: Endogenous MW (kDa): 273 SOURCE: Rabbit

Order Guidelines

1. Price & Stock Available on Request. 📧Click to send email to: service@iright.com

2. Please DO NOT make payment before confirmation.

3. Minimum order value of $1,000 USD required.

Collaboration

Tony Tang

📧Email: Tony.Tang@iright.com

📱Mobile/WhatsApp/Wechat: +86-17717886924